Crémieux Profile picture
Sep 23, 2024 7 tweets 3 min read Read on X
The FBI has finally released crime statistics for 2023!

Let's have a short thread.

First thing up is recent violent crime trends: Image
Now let's focus in on homicides.

The homicide statistics split by race show the same distribution they have for years. Image
As with every crime, it's still men doing the killing, but it's also largely men doing the dying. Image
What about Hispanics? Their data is still a mess, but here it is if you're interested. Image
The age-crime curve last year looked pretty typical. How about this year?

Same as always. Victims and offenders still have highly similar, relatively young ages. Image
Everything else, from locations to motives to weapons is pretty similar to previous years. What's different is that the OP might show incorrect numbers.

For the past two years, the FBI has silently updated their numbers after about two weeks.

You can use the web archive to see that the data from the OP is the data shown at release last year, and the data from 2023 is the 2022 data with the FBI's suggested reductions (i.e., -11.6% homicides, -2.8% aggravated assaults, -0.3% robberies, etc.).

But you can see on their site now that they've adjusted the numbers up, so the reduction they suggested has brought us down to a figure that's less impressive than my chart shows. The difference isn't huge so I showed the OP without updating to their new data.

For reference, 2022 as reported then had a homicide rate of 6.3/100k, and they silently updated that to 7.48/100k. The 2023 data they provided today actually has a murder rate of 6.61/100k, higher than last year's initially-reported number, but lower than the updated number. To make matters worse, if you use their Expanded Homicides Report, you get a rate of 5.94 for 2022 and 5.24 for 2023.

Methodology matters and we get to see inconsistency in this year's data, not even data that's been updated or anything. It's a mess, so take everything with a grain of salt and, in the interest of caution, only interpret trends. Trends are mostly common between all data sources even if the absolute magnitudes are off, constantly updated, etc.

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Crémieux

Crémieux Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @cremieuxrecueil

Jun 18
I think a major 'theme' of my account is that the world is rarely surprising or overwhelmingly complex, that most things are ordinary and not mysterious when you look at them closely.

A short review thread🧵 Image
My latest article is about how major breaks in trends usually signal that the data changed rather than that the world changed.

There are few exceptions. One of them is vaccination, which genuinely does cause a massive break in disease incidence: Image
At one point in time, I believed a common, "received" piece of knowledge: that Nigerians were a "special" immigrant group that perform "exceptionally".

Someone here told me I was wrong, that I should look into that. So I did, and, indeed, I was wrong.

Image
Read 22 tweets
Jun 17
There are a few other drugs that have successfully and safely helped with weight loss. I'll post a few examples.

Here's Tesofensine, an SNDRI that suppresses appetite: Image
Phentermine, often as phentermine-topiramate, is an NDRA that suppresses appetite: Image
Orlistat is a pancreatic lipase inhibitor that works by blocking fat absorption: Image
Read 24 tweets
Jun 16
Yet another grooming gang profile has been released.

The suspects were almost two-thirds Pakistani. Image
This lines up with the findings of several earlier operations:

This also lines up with a more comprehensive investigation:

Read 4 tweets
Jun 16
Novo Nordisk failed to pay a small patent maintenance fee in Canada a few years ago.

As a result, a generic version of Ozempic will be available there soon.

The HHS can exploit this oversight to decisively end the chronic disease crisis, if it has the courage🧵 Image
First, a bit of background.

Novo Nordisk is a pharmaceutical company that makes drugs for diabetes.

The blockbuster drug that turned them into a major pharma player is semaglutide, which they sell under the brand names Wegovy, Ozempic, and Rybelsus. Image
Semaglutide has been amazingly successful.

It greatly assists in the management of diabetes, and it causes major weight loss with minimal side effects for most.

Its utility for treating obesity is somewhere between an earlier daily version (liraglutide) and bariatric surgery. Image
Read 26 tweets
Jun 14
One of the reasons I'm bullish on Eli Lilly over Novo Nordisk is that I don't think Novo can hack it against a much more R&D-focused American company run by a shrewd corporate climber.

Novo seems like its leadership is much more naïve. Image
Eli Lilly's investments just seem to be superior to Novo's, which have mostly been falling through recently.

The best Novo seems capable of doing now is mimicking Eli Lilly's next drug, retatrutide.

If they were smart, they would do some collaborations.

But I am a believer in something like a Great Man theory of business success.

There's lots of evidence for it. For example, when high-earning business owners die, the profits of their businesses drop right away.

Turns out, they were compensated for real value to the business. Image
Read 5 tweets
Jun 13
Companies are rapidly improving on GLP-1 weight loss.

Regeneron just paired semaglutide (Ozempic/Wegovy) with a myostatin inhibitor and the result was...

- More fat loss
- Less muscle loss Image
The problem is that adding things to GLP-1RA treatment might lead to more side effects and worse adherence as a result.

But that seems to not be a concern with a low-dose myostatin inhibitor: added side effects only become concerning with more advanced treatment. Image
The weight loss that comes with using GLP-1RAs is already similar to normal weight loss compositionally.

These new drugs thus present with an interesting prospect: that pharmacotherapy-driven weight loss will soon be superior to normal weight loss!Image
Read 8 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us!

:(